This industry report and any articles based on it are provided as part of a commercial service to entities mentioned and is intended for informational purposes only. It is designed to offer an overview of the current landscape following the enactment of the Cannabis Act in Germany and its potential implications for the medical cannabis industry, including a focus on specific companies such as InterCure. The Author is compensated to write the content within this report and it does not constitute medical, financial, legal, or any other form of professional advice. Readers are advised to conduct their own research and due diligence and to consult professional advisors in the relevant fields with respect to their specific circumstances or before making any decisions based on the information provided in this report. The information contained in this report is based on sources believed to be reliable, but its accuracy and completeness cannot be guaranteed. The report reflects observations and opinions as of the date of publication and all information contained herein is subject to change without notice. The publication of this report does not in any way constitute an endorsement of any particular company, individual, product, or strategy, nor does it suggest that any investment, health, or legal decisions be made based on the information provided herein. The authors and publishers of this report disclaim any liability, loss, or risk taken by individuals who directly or indirectly act on the information contained herein. Readers are responsible for their own actions and decisions.
